FdaApplication
NDA 212728
Identifiers
- fda_app_no: NDA212728
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2020-02-27 |
Revenue by product
NURTEC ODT
| Period | Revenue |
|---|---|
| Q2 2026 | $421.0M |
| Q1 2026 | $353.0M |
| Q3 2025 | $412.0M |
| Q2 2025 | $359.0M |
| Q1 2025 | $248.0M |
| Q3 2024 | $337.0M |
| Q2 2024 | $356.0M |
| Q1 2024 | $178.0M |
| Q4 2023 | $282.0M |
| Q3 2023 | $233.0M |
| Q2 2023 | $247.0M |
| Q1 2023 | $167.0M |
| Q4 2022 | $212.0M |
| Q3 2022 | $0.0M |
| Q2 2022 | $0.0M |
| Q1 2022 | $1.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NURTEC ODT | RIMEGEPANT SULFATE | EQ 75MG BASE | TABLET, ORALLY DISINTEGRATING;ORAL |
1 product